Cervical Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Cervical Cancer, including details on symptoms, vaccine, screening, treatment, human papilloma virus (hpv), information.

Volume 5 (2008), Issue 7 (July)

1. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis.
   Am J Epidemiol, 168(2): 123-37. [Abstract] [Full-text]
2. Invited commentary: is monitoring of human papillomavirus infection for viral persistence ready for use in cervical cancer screening?
   Am J Epidemiol, 168(2): 138-44; discussion 145-8. [Abstract] [Full-text]
3. Human Papillomavirus type distribution in invasive cervical cancer in Uganda.
   BMC Infect Dis, 8: 85. [Abstract] [Full-text]
4. No association of the POLI Thr706Ala polymorphism with the risk of cervical carcinoma.
   Eur J Surg Oncol, 34(8): 916-20. [Abstract] [Full-text]
5. Association between dense CADM1 promoter methylation and reduced protein expression in high-grade CIN and cervical SCC.
   J Pathol, 215(4): 388-97. [Abstract] [Full-text]
6. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India.
   Br J Cancer, 99(2): 230-8. [Abstract] [Full-text]
7. Do women >or=50 years of age need as much screening as women <50 years after they have had negative screening results?
   Br J Cancer, 99(2): 239-44. [Abstract] [Full-text]
8. Factors predicting tumour regression in locally advanced cervical adenocarcinoma treated with balloon-occluded intra-arterial chemotherapy.
   Br J Radiol, 81(968): 659-65. [Abstract] [Full-text]
9. Mucoid impaction secondary to mucin-producing metastatic adenocarcinoma of the cervix.
   Br J Radiol, 81(968): e201-3. [Abstract] [Full-text]
10. Conditionally replicating E1B-deleted adenovirus driven by the squamous cell carcinoma antigen 2 promoter for uterine cervical cancer therapy.
    Cancer Gene Ther, 15(8): 526-34. [Abstract] [Full-text]
11. An in vitro multistep carcinogenesis model for human cervical cancer.
    Cancer Res, 68(14): 5699-705. [Abstract] [Full-text]
12. Dosimetric comparison of bone marrow-sparing intensity-modulated radiotherapy versus conventional techniques for treatment of cervical cancer.
    Int J Radiat Oncol Biol Phys, 71(5): 1504-10. [Abstract] [Full-text]
13. Estimation of setup uncertainty using planar and MVCT imaging for gynecologic malignancies.
    Int J Radiat Oncol Biol Phys, 71(5): 1511-7. [Abstract] [Full-text]
14. Effect of high-dose-rate 192Ir source activity on late rectal bleeding after intracavitary radiation therapy for uterine cervix cancer.
    Int J Radiat Oncol Biol Phys, 71(5): 1329-34. [Abstract] [Full-text]
15. Postradiotherapy morbidity in long-term survivors after locally advanced cervical cancer: how well do physicians' assessments agree with those of their patients?
    Int J Radiat Oncol Biol Phys, 71(5): 1335-42. [Abstract] [Full-text]
16. Monitoring of viral cancer progression using FTIR microscopy: a comparative study of intact cells and tissues.
    Biochim Biophys Acta, 1780(9): 1038-46. [Abstract] [Full-text]
17. Radical vaginal trachelectomy vs. radical hysterectomy for small early stage cervical cancer: a matched case-control study.
    Gynecol Oncol, 110(2): 168-71. [Abstract] [Full-text]
18. Human papillomavirus genotype distribution in low-grade squamous intraepithelial lesions in France and comparison with CIN2/3 and invasive cervical cancer: the EDiTH III study.
    Gynecol Oncol, 110(2): 179-84. [Abstract] [Full-text]
19. Positron emission tomography in evaluating the feasibility of curative intent in cervical cancer patients with limited distant lymph node metastases.
    Gynecol Oncol, 110(2): 172-8. [Abstract] [Full-text]
20. A robust ex vivo model for evaluation of induction of apoptosis by rhTRAIL in combination with proteasome inhibitor MG132 in human premalignant cervical explants.
    Int J Cancer, 123(6): 1457-65. [Abstract] [Full-text]
21. Does lowering the screening age for cervical cancer in The Netherlands make sense?
    Int J Cancer, 123(6): 1403-6. [Abstract] [Full-text]
22. Prevalence of oncogenic human papillomavirus infection in an organised screening population in Finland.
    Int J Cancer, 123(6): 1344-9. [Abstract] [Full-text]
23. The role of p38 MAPK and JNK in Arsenic trioxide-induced mitochondrial cell death in human cervical cancer cells.
    J Cell Physiol, 217(1): 23-33. [Abstract] [Full-text]
24. Human papillomavirus type 16 variants in cervical cancer from an admixtured population in Brazil.
    J Med Virol, 80(9): 1639-45. [Abstract] [Full-text]

© 2004-2010 Cervical Cancer Research Today. All Rights Reserved.